ARMP:Armata Pharmaceuticals Inc Snapshot | Charting | News | Options
$7.32   0.00%  $0.00 NYSE MKT LLC 4:05p ET
November 12 '25 		Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update PR Newswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
     PR Newswire

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2025, and provided a corporate update.

    Full Story →

    Headline News
    Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
    7:00a ET November 10 '25 PR Newswire
    Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
    11:10a ET October 22 '25 PR Newswire
    Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
    7:01a ET October 14 '25 PR Newswire
    More News →
    Day  0.00%Week  17.9%Month  115%More Charting →
    November 14 '25. Markets Closed.
    Last $7.32
    Day change   0.00%$0.00
    Open $NA
    Gap at open $NA
    Previous close $7.32
    Trading volume 100
    10 Day avg vol. 131,974
    Shares out. 36.3Mil
    Market cap. $265.9Mil
    Trading activity Below Avg.
    Previous data from yesterday, November 14 '25.

    Historical Price Performance
    3 month   188% 
    6 month   249% 
    1 year   204% 
    2 year   230% 

    Earnings
    Previous 12m -$0.71
    Next 12m Estimate -$1.54
    P/E ratio --
    Revenue 7Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2025 All rights reserved.